Evidence map›Paper›PMID 28673855›Full record

ArticleJournal of virological methods2017

Immiscible phase filter extraction and equivalent amplification of genotypes 1-6 of hepatitis C RNA: The building blocks for point-of-care diagnosis.

Mário F Neto, Matthew A Butzler, Jennifer L Reed, Xiang Rui, Mark J Fisher, David M Kelso, Sally M McFall

Open access · hybridAbstract read
In one paragraph

Article in Journal of virological methods, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mário F NetoCenter for Innovation in Global Health Technologies, Northwestern University, Evanston, IL 60208, USA; University of Illinois Incubator Lab Facility, Chicago, IL 60612, USA.
Matthew A ButzlerCenter for Innovation in Global Health Technologies, Northwestern University, Evanston, IL 60208, USA.
Jennifer L ReedCenter for Innovation in Global Health Technologies, Northwestern University, Evanston, IL 60208, USA.
Xiang RuiCenter for Innovation in Global Health Technologies, Northwestern University, Evanston, IL 60208, USA.
Mark J FisherCenter for Innovation in Global Health Technologies, Northwestern University, Evanston, IL 60208, USA.
David M KelsoCenter for Innovation in Global Health Technologies, Northwestern University, Evanston, IL 60208, USA.
Sally M McFallCenter for Innovation in Global Health Technologies, Northwestern University, Evanston, IL 60208, USA. Electronic address: s-mcfall@northwestern.edu.
Center for Innovation · USNorthwestern University · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Active Viral Hepatitis Diagnostics to Support Prevention/Treatment of HCCUH2CA189965 · NCI · NORTHWESTERN UNIVERSITY · PI MURPHY, ROBERT LEO · 2014 to 2015
$896k
NCI NIH HHS UH2 CA189965NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

The lack of hepatitis C virus (HCV) diagnostic tests designed for use in decentralized settings is a major obstacle for providing access to treatment and prevention services particularly in low and middle income countries. Here we describe the development and validation of two building blocks of the HCV Quant Assay, a test in development for point-of-care use: 1) an RT-qPCR assay with noncompetitive internal control that equivalently detects the 6 major HCV genotypes and 2) an automated sample prep method using immiscible phase filter technology. This novel assay has wide dynamic range of HCV quantification and a limit of detection of 30IU/ml with 200μl specimen volume. In a preliminary study of 61 clinical specimens, the HCV Quant Assay demonstrated 100% sensitivity and specificity and gave comparable viral load results across 4 logs of IU/ml when compared to the Abbott RealTime HCV Assay.

Indexed as

Point-of-Care SystemsGenotypeHepacivirusHepatitis CHumansReagent Kits, DiagnosticReal-Time Polymerase Chain ReactionReproducibility of ResultsRNA, ViralSensitivity and SpecificitySerologic TestsViral LoadReagent Kits, DiagnosticRNA, ViralHCVRT-qPCRSample prepViral load monitoring

Identifiers

PMID28673855
PMCPMC5592153
OpenAlexW2725723093

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.